Hello, everyone, and how are you today? We are doing just fine, thank you, especially since a warm and shiny sun is enveloping the Pharmalot campus. Our short person has left for the local schoolhouse and our official mascots are ensconced in their corners, snoozing away. We, however, have no time for napping. A busy day awaits and, no doubt, you can relate. So grab a cup of stimulation — or a water bottle, if you prefer — and let us all get cracking. Here are some items of interest to help you along. Hope you conquer the world today and, as always, keep in touch …
Takeda Pharmaceutical (TKPYY) agreed to pay $62 billion to buy Shire (SHPG) following a months-long battle that will create the world’s eighth-largest drug-maker with combined sales of $30 billion. The move extends Takeda’s reach in key U.S. and European markets, although the company will borrow cash to fund the deal, worrying some shareholders. The deal means Takeda will now earn roughly half of its revenue in the U.S. — where companies have greater flexibility to charge what they like — up from one-third of its revenue previously, The Wall Street Journal says. About 7 percent of 52,000 workers will lose jobs.
About the Author Reprints
